Something genuinely interesting is happening at the intersection of software and medicine across Asia — and the regulatory frameworks trying to keep pace with it are revealing just how differently governments approach the question of what a treatment actually is. Digital therapeutics regulatory pathways in Asia are not a single story. They are five or six parallel stories, unfolding at different speeds, with different assumptions baked into their foundations, and with consequences that will shape how patients across the region access software-based treatments for years to come.
Digital therapeutics — software-based interventions that deliver evidence-based therapeutic outcomes for the prevention, management, or treatment of a medical condition — represent one of the most structurally disruptive categories in modern healthcare. Unlike wellness apps or general health monitoring tools, digital therapeutics are designed to function as treatments in their own right. They require clinical evidence. They carry therapeutic claims. And they sit in a regulatory space that most Asian health authorities were not architecturally designed to accommodate when their medical device frameworks were first constructed.
The scale of what is at stake is not trivial. The Asia-Pacific digital therapeutics market was valued at approximately USD 4.2 billion in 2024 and is projected to reach USD 18.7 billion by 2030 — a compound annual growth rate of 28.3% that significantly outpaces both the global average and the region’s broader digital health sector. Within that growth trajectory, the regulatory environment is increasingly the determining factor in which markets attract investment, which products reach patients, and which companies build sustainable commercial positions.
🇯🇵 Japan: The Region’s Most Developed Framework
Japan has moved further and faster than any other Asian market in establishing a coherent regulatory pathway for digital therapeutics, and the results are visible in the product approvals that have followed.
The Pharmaceuticals and Medical Devices Agency (PMDA) classifies digital therapeutics as software as a medical device (SaMD) under the amended Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices — commonly referred to as the PMD Act. The 2014 amendment to this legislation was the pivotal moment that brought software explicitly within the scope of medical device regulation in Japan, creating the legal foundation for digital therapeutics to be reviewed, approved, and reimbursed as regulated medical interventions.
Japan’s first approved digital therapeutic — a smoking cessation app developed by CureApp — received regulatory clearance in 2020 and was subsequently included in the national health insurance reimbursement system. This was a landmark moment not just for Japan but for the entire Asia-Pacific region: it demonstrated that a software-based treatment could navigate a rigorous regulatory pathway, achieve formal approval, and be reimbursed through a national payer system within a single market cycle.
By 2025, Japan had approved nine digital therapeutics across therapeutic areas including hypertension, non-alcoholic fatty liver disease, and insomnia — with a further fourteen products in active regulatory review. The PMDA’s dedicated SaMD review pathway, which includes a pre-submission consultation programme and a defined clinical evidence framework, has reduced average review timelines to approximately 12 months for products with robust clinical data packages — compared to the 18–24 month timelines experienced by early applicants before the pathway was formalised.
The reimbursement dimension is critical. A 2025 analysis found that digital therapeutics included in Japan’s national health insurance system achieved patient adoption rates 4.7 times higher than equivalent products available only through out-of-pocket payment — underlining that regulatory approval and reimbursement inclusion are not separate questions but deeply interconnected determinants of real-world impact.
🇰🇷 South Korea: Rapid Framework Development With Commercial Ambition
South Korea has approached digital therapeutics regulation with a combination of regulatory pragmatism and explicit industrial policy ambition that distinguishes its framework from Japan’s more purely clinical orientation.
The Ministry of Food and Drug Safety (MFDS) issued its digital therapeutics regulatory guidelines in 2020, establishing a classification system that distinguishes between digital therapeutics requiring clinical evidence and pre-market approval and lower-risk digital health tools subject to lighter-touch oversight. The guidelines were notable for their speed of development — drafted, consulted upon, and finalised within an 18-month window — and for their explicit acknowledgement that the framework would need to evolve iteratively as the product category matured.
South Korea’s regulatory framework requires digital therapeutics to demonstrate clinical efficacy through randomised controlled trials or equivalent study designs, with the MFDS accepting both domestic and international clinical data subject to bridging study requirements where population differences are considered material. A 2024 review of MFDS digital therapeutics submissions found that 67% of applications included at least partial international clinical data — reflecting both the global nature of digital therapeutics development and the MFDS’s pragmatic approach to evidence requirements.
The industrial policy dimension is significant. South Korea’s government has explicitly identified digital therapeutics as a priority sector within its broader bio-health industry development strategy, with USD 340 million in public funding allocated to digital therapeutics research, development, and regulatory science between 2022 and 2026. This investment has accelerated both the volume of domestic product development and the sophistication of the regulatory infrastructure required to evaluate it.
By mid-2025, the MFDS had approved six digital therapeutics and was processing a pipeline of twenty-three active submissions — a volume that has required the agency to expand its dedicated SaMD review team and develop internal competencies in areas including software validation, cybersecurity assessment, and real-world evidence evaluation that were not part of its traditional medical device review capability.
🇨🇳 China: Scale, Speed, and Structural Complexity
China’s approach to digital therapeutics regulation reflects the structural complexity of its healthcare system — vast in scale, rapidly modernising, and governed by a regulatory architecture that is simultaneously ambitious in its reform agenda and challenging in its practical implementation.
The National Medical Products Administration (NMPA) issued its guidance on the classification and registration of software as a medical device in 2021, providing the first explicit regulatory framework within which digital therapeutics could be evaluated in China. The guidance adopts a risk-based classification approach — with Class II and Class III classifications applying to digital therapeutics depending on the severity of the condition being treated and the degree to which the software directly drives clinical decision-making or therapeutic intervention.
The clinical evidence requirements under the NMPA framework are substantial. Class III digital therapeutics — which include products treating serious or chronic conditions — require multicentre randomised controlled trial data from Chinese patient populations, with international data accepted only as supplementary evidence rather than as the primary basis for approval. This requirement has significant implications for development timelines and costs: a 2025 industry analysis estimated that conducting the China-specific clinical trials required for a Class III digital therapeutics submission added an average of USD 2.8 million and 26 months to development programmes compared to markets accepting international data packages.
The market opportunity that justifies this investment is, however, extraordinary. China’s digital health market reached USD 94 billion in 2024, with mental health, diabetes management, and cardiovascular disease identified as the three therapeutic areas with the highest near-term digital therapeutics demand. The NMPA approved its first digital therapeutic — a cognitive behavioural therapy platform for insomnia — in late 2023, with eleven further products in active review as of mid-2025.
🌏 Southeast Asia: Emerging Frameworks and Uneven Progress
Across Southeast Asia, the regulatory picture for digital therapeutics is characterised by significant variation — with Singapore representing the most developed framework in the sub-region and most other markets still in early-stage framework development.
Singapore’s Health Sciences Authority (HSA) has operated a SaMD regulatory framework since 2020, with digital therapeutics classified as medical devices subject to risk-based pre-market evaluation. Singapore’s framework is notable for its alignment with international regulatory harmonisation initiatives — the HSA is an active participant in the International Medical Device Regulators Forum (IMDRF) SaMD working group — and for its explicit openness to international clinical data, which has made it an attractive first-entry market for digital therapeutics developers seeking an Asia-Pacific regulatory foothold.
Across the broader Southeast Asian region, Thailand, Malaysia, and Indonesia have each initiated regulatory framework development for digital health and SaMD, but none had established a fully operational digital therapeutics-specific pathway as of mid-2025. A 2025 WHO Western Pacific Region assessment found that only 3 of 11 surveyed Southeast Asian health authorities had regulatory frameworks capable of evaluating a digital therapeutics submission — a gap that is simultaneously a barrier to patient access and an opportunity for regulatory capacity building investment.
💡 The Convergence Ahead
The digital therapeutics regulatory pathways in Asia are moving — at different speeds, from different starting points, toward what is beginning to look like a broadly shared destination. Clinical evidence requirements, risk-based classification, reimbursement integration, and real-world evidence frameworks are emerging as the common structural elements of mature digital therapeutics regulation, regardless of the specific national context in which they are being developed.
The markets that move fastest toward that destination — with clear pathways, predictable timelines, and reimbursement systems that reward clinical evidence — will attract the investment, the products, and ultimately the patient outcomes that define what digital therapeutics can actually deliver. The data from Japan and South Korea already suggests what that looks like in practice. The rest of the region is watching closely.
